<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Commercialization of the &#8220;cancer stem cell&#8221; concept</title>
	<atom:link href="http://hematopoiesis.info/2008/04/21/commercialization-of-the-cancer-stem-cell-concept/feed/" rel="self" type="application/rss+xml" />
	<link>http://hematopoiesis.info/2008/04/21/commercialization-of-the-cancer-stem-cell-concept/</link>
	<description>Blood Stem Cell &#38; Cell Therapy Trends</description>
	<lastBuildDate>Fri, 20 Jan 2012 01:41:14 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
	<item>
		<title>By: Alex</title>
		<link>http://hematopoiesis.info/2008/04/21/commercialization-of-the-cancer-stem-cell-concept/#comment-298</link>
		<dc:creator>Alex</dc:creator>
		<pubDate>Wed, 23 Apr 2008 05:46:57 +0000</pubDate>
		<guid isPermaLink="false">http://hematopoiesis.info/2008/04/21/commercialization-of-the-cancer-stem-cell-concept/#comment-298</guid>
		<description>Yes, anti-CSC drugs is the second line of therapy.
First is surgical cytoreduction if it&#039;s solid tumor (before metastatic stage) or after BMT/chemotherapy if it&#039;s leukemia. In any case, especially if it&#039;s metastatic process, anti-CSC therapy is integrated in the &quot;common protocol&quot;.

the best quote from the article:

&lt;blockquote&gt;The main thing is to ensure that we eliminate the malignant cancer stem cells only without affecting the normal stem cells. 
&lt;strong&gt;Whether we&#039;ll be able to do this is the billion dollar question that everyone wants to answer&lt;/strong&gt;.&lt;/blockquote&gt;


by Michael Clarke</description>
		<content:encoded><![CDATA[<p>Yes, anti-CSC drugs is the second line of therapy.<br />
First is surgical cytoreduction if it&#8217;s solid tumor (before metastatic stage) or after BMT/chemotherapy if it&#8217;s leukemia. In any case, especially if it&#8217;s metastatic process, anti-CSC therapy is integrated in the &#8220;common protocol&#8221;.</p>
<p>the best quote from the article:</p>
<blockquote><p>The main thing is to ensure that we eliminate the malignant cancer stem cells only without affecting the normal stem cells.<br />
<strong>Whether we&#8217;ll be able to do this is the billion dollar question that everyone wants to answer</strong>.</p></blockquote>
<p>by Michael Clarke</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Jae-Won Shin</title>
		<link>http://hematopoiesis.info/2008/04/21/commercialization-of-the-cancer-stem-cell-concept/#comment-297</link>
		<dc:creator>Jae-Won Shin</dc:creator>
		<pubDate>Tue, 22 Apr 2008 20:15:51 +0000</pubDate>
		<guid isPermaLink="false">http://hematopoiesis.info/2008/04/21/commercialization-of-the-cancer-stem-cell-concept/#comment-297</guid>
		<description>Interesting article. It will be important to define if cancer stem cell is a useful target for patients with terminal illness. I envision that cancer stem cell is a target for the key but second line of cancer treatment: remove aggressive tumor first, then remove cancer stem cells to prevent relapse.</description>
		<content:encoded><![CDATA[<p>Interesting article. It will be important to define if cancer stem cell is a useful target for patients with terminal illness. I envision that cancer stem cell is a target for the key but second line of cancer treatment: remove aggressive tumor first, then remove cancer stem cells to prevent relapse.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

